Loading
PROMISE V2 is a standard way to read and report PSMA PET scans in prostate cancer, describing where the cancer is with a molecular-imaging version of TNM (miTNM) and tracking change in trials.
The prostate cancer molecular imaging standardized evaluation (PROMISE) criteria describe disease extent on PSMA PET as molecular imaging TNM. PROMISE V2 (Seifert and colleagues, European Urology 2023) updates miTNM, improves assessment of local disease, slightly modifies the PSMA-expression score, and adds a framework of parameters to record over time in clinical trials, which can feed PSMA PET progression (PPP) or RECIP. A low PSMA-expression score predicted shorter survival after lutetium-177 PSMA therapy in the studies reviewed.
Showing the technology this term belongs to: PSMA PET.
Shares PSMA PET progression and response consensus (PPP), RECIP 1.0 (PSMA PET response in prostate cancer), Prostate cancer.
Shares Disease-specific staging and risk systems (FIGO, Ann Arbor, IPI, R-ISS, ELN, IMDC), TNM staging.
Shares Disease-specific staging and risk systems (FIGO, Ann Arbor, IPI, R-ISS, ELN, IMDC), TNM staging.
Shares Disease-specific staging and risk systems (FIGO, Ann Arbor, IPI, R-ISS, ELN, IMDC), TNM staging.
Shares Disease-specific staging and risk systems (FIGO, Ann Arbor, IPI, R-ISS, ELN, IMDC), TNM staging.
Shares Disease-specific staging and risk systems (FIGO, Ann Arbor, IPI, R-ISS, ELN, IMDC), TNM staging.
Shares Disease-specific staging and risk systems (FIGO, Ann Arbor, IPI, R-ISS, ELN, IMDC), TNM staging.
Shares Disease-specific staging and risk systems (FIGO, Ann Arbor, IPI, R-ISS, ELN, IMDC), TNM staging.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/